At the news
? BULLISHIMPACT 6/10 6-K filed Jun 30, 2026 at 20:50 ET
Mesoblast received a BLA filing number from the FDA and requested a modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. The drug has Orphan Drug and RMAT designations, and the company highlighted recent FDA guidance on regulatory flexibility for orphan rare diseases. This is a positive regulatory milestone but does not guarantee approval.
- Received BLA filing number from FDA for rexlemestrocel-L in end-stage heart failure with LVADs
- Requested modular review of the BLA
- Rexlemestrocel-L has Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations
- FDA recently issued draft guidance on flexibility for demonstrating substantial evidence of effectiveness for orphan rare diseases
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access